Acute Respiratory Distress Syndrome
Conditions
Brief summary
The aim of the study is to evaluate the safety, improvement of clinical symptoms and laboratory parameters of convalescent immune plasma treatment in severe Covid-19 patients with ARDS.
Detailed description
The aim of the study is to evaluate the safety, improvement of clinical symptoms with hypoxemia, metabolic and laboratory parameters of patients with convalescent immune plasma treatment in severe Covid-19 patients followed up in critical care unit.
Interventions
OTHERConvalescent Immune Plasma
One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
Sponsors
Bagcilar Training and Research Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
Clinical diagnosis of Covid-19
Exclusion criteria
Age lower than 18 Lower plasma IgA levels PaO2/FiO2 higher than 300 mmHg SpO2 higher than 90
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma fibrinogen level | 7. day | Coagulopathy |
| D-Dimer level | 7. day | Hypercoagulability |
| C-Reactive protein level | 7. day | Infection markers |
| Plasma procalcitonin level | 7. day | Infection markers |
| Plasma ferritin level | 7. day | Acute phase reactant |
| Lymphocyte count | 7. day | Infection markers |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Partial Oxygen Saturation level | 7. day | Arterial oxygenation |
| Arterial Oxygen level | 7. day | Arterial oxygenation |
| Fractional Inspired Oxygen Level | 7. day | Arterial oxygenation |
Countries
Turkey (Türkiye)
Outcome results
None listed